Shifting Goalposts For Vaccine Cos As Lambda Variant Rears Head

Multiple Vaccines Show Delta Efficacy

Studies point to Johnson & Johnson, Pfizer and Bharat Biotech’s vaccines neutralizing the Delta variant of SARS-CoV-2, even if efficacy is lower compared to the original strain. This follows positive news from other vaccine companies but will the Lambda variant cause a setback?

Coronavirus Variant Emerging/Mutated SARS-CoV-2
The Changing Colors Of SARS-CoV-2 Present A Challenge To Vaccine Makers • Source: Alamy

Global manufacturers developed vaccines in record time when COVID-19 hit but "there’s no rest for the wicked." Even as Johnson & JohnsonPfizer Inc./BioNTech SE and Bharat Biotech added to the chorus of producers saying their vaccines work against the highly contagious Delta variant, another viral iteration termed Lambda has now reared its head.

While it is widely believed that mRNA vaccines can quickly be adapted to counter variants and inactivated virus vaccines are meant to have a robust design, each time a new variant shows up vaccine makers have to convince

More from R&D

More from Scrip

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By 

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By 

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.